| Name | Title | Contact Details |
|---|
The Blood Bank of Hawaii is a non-profit organization that provides lifesaving blood products to 11 civilian hospitals on Oahu and eight civilian hospitals on the neighbor islands. Typical uses for the blood include surgical procedures, treatment of
At Blue Shield of California, we`re focused on fundamentally improving the ways in which members can access care and use their coverage. We`re investing in talented employees and new technologies to create an unrivaled member experience that elevates expectations and achieves our mission of making health care more accessible and affordable than ever. Today we are the third-largest health plan in the state and we`re dedicated to transforming the healthcare industry. Headquartered in San Francisco, with 18 additional offices across California, we`re proud to service over 4 million members and employ more than 6,000 people. We are an independent member of the Blue Shield Association. Blue Shield of California complies with applicable state laws and federal civil rights laws, and does not discriminate on the basis of race, color, national origin, ancestry, religion, sex, marital status, gender, gender identity, sexual orientation, age, or disability. Blue Shield of California cumple con las leyes estatales y las leyes federales de derechos civiles vigentes, y no discrimina por motivos de raza, color, país de origen, ascendencia, religión, sexo, estado civil, género, identidad de género, orientación sexual, edad ni discapacidad.
Hospice El Paso, Inc. is a El Paso, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Precision Medical Products is a Denver, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.